Global data center
Cancer statistics make more sense when the limits are visible.
A plain-language starting point for cancer prevalence, mortality, costs, treatment access, and barriers around the world.
10M
Cancer deaths worldwide
WHO estimated nearly 10 million cancer deaths globally in 2024.
38%
Potentially preventable
WHO estimates this share can be prevented with current prevention strategies.
185
Countries in GLOBOCAN
IARC publishes estimates for 36 cancer types across 185 countries.
$21B
U.S. patient burden
NCI reported 2019 U.S. patient out-of-pocket plus time costs above $21 billion.
What these numbers can and cannot show
Worldwide cancer statistics answer more than which cancers are common. Read together, they connect burden, cost, treatment access, and the barriers that keep care from reaching people.
Cancer statistics are best read as maps, not personal predictions. They can show where prevention, screening, diagnosis, treatment, and palliative care are reaching people, and where systems are leaving people behind.
Official global estimates also have limits. Some countries have strong cancer registries; others depend more heavily on modeled estimates. So before comparing two countries, it is worth knowing whether each number was measured or modeled, how old it is, and whether underdiagnosis makes it look lower than the reality.
- Incidence, mortality and prevalence all measure different things, and can move in opposite directions.
- Patterns by race, ethnicity, income, rural access or insurance status often explain more than the country-level figure does.
- What treatment a country can actually deliver — surgery, radiation, pathology, essential medicines, palliative care — shapes survival as much as incidence does.
- Travel distance, drug cost, shortages, late diagnosis, stigma, conflict, language and missing registries all sit behind the numbers.
Numbers that need context
A high cancer rate can mean more risk, better detection, older population age, stronger registries, or some mix of all of those. Mortality may reflect biology, stage at diagnosis, treatment access, and follow-up care.
That is why every chart here comes with plain-language notes. A breast cancer rate, for example, can reflect screening access and registry strength as much as underlying biology. A survival comparison can reflect stage at diagnosis, treatment availability, follow-up time, and how deaths are recorded.
Costs need the same caution. Patient costs, insurer payments, public spending, lost wages, travel, caregiver time, and national economic burden are different measurements. They should not be collapsed into one scary number without explaining what is counted.
- Incidence is not the same as deathIncidence counts newly diagnosed cancer. Mortality counts deaths. A place can find more cancers early and still have better survival.
- Prevalence shows people living after cancerPrevalence includes people alive after diagnosis. It can rise when detection and survival improve.
- Costs include more than hospital billsTransportation, missed work, caregiver time, housing, medicine, insurance cost sharing, and debt can all shape access.
What global data still cannot tell you
Some of the comparisons people most want do not exist yet in any reliable form. It helps to know which ones, so that a gap in the data is not mistaken for an answer.
For low-resource settings, public data is often thin — and missing data usually means missing registry capacity, not missing cancer. That distinction matters. A country with few recorded cases may simply have no way to record them.
These are the comparisons that are hardest to find anywhere today:
- Cancer treatment cost by cancer type, with separate views for patient costs and health-system costs when sources allow it.
- Treatment effectiveness and survival summaries that state stage, biomarker, country, and treatment era instead of treating cancer as one disease.
- Low-resource country pages that explain what information is missing and where official data is limited.
- Plain-language data notes so readers know when a chart is measured, estimated, modeled, old, or incomplete.
Related places on Cancer Explained
Sources used for this page
- WHO Cancer fact sheetGlobal cancer burden, prevention, treatment access, and palliative care context.
- IARC Global Cancer ObservatoryInternational estimates for incidence, mortality, and prevalence.
- NCI: Managing Cancer CostsPlain-language guidance on treatment costs and insurance questions.
- NCI Annual Report economic burden releaseU.S. patient out-of-pocket and time-cost estimates.